NuVasive Stock Price, News & Analysis (NASDAQ:NUVA)

$50.29 -1.70 (-3.27 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$51.99
Today's Range$48.41 - $51.50
52-Week Range$48.41 - $81.68
Volume2.11 million shs
Average Volume1.51 million shs
Market Capitalization$2.56 billion
P/E Ratio42.26
Dividend YieldN/A
Beta0.77

About NuVasive (NASDAQ:NUVA)

NuVasive logoNuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNASDAQ:NUVA
CUSIP67070410
Phone+1-858-9091800

Debt

Debt-to-Equity Ratio0.76%
Current Ratio2.85%
Quick Ratio1.51%

Price-To-Earnings

Trailing P/E Ratio42.2605042016807
Forward P/E Ratio26.33
P/E Growth1.48

Sales & Book Value

Annual Sales$962.07 million
Price / Sales2.66
Cash Flow$4.07 per share
Price / Cash12.35
Book Value$13.91 per share
Price / Book3.62

Profitability

Trailing EPS$1.19
Net Income$37.14 million
Net Margins6.36%
Return on Equity13.65%
Return on Assets6.17%

Miscellaneous

Employees2,200
Outstanding Shares50,970,000

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How will NuVasive's stock buyback program work?

NuVasive declared that its Board of Directors has authorized a stock repurchase plan on Wednesday, October 25th 2017, which authorizes the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its stock is undervalued.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) posted its quarterly earnings data on Tuesday, October, 24th. The medical device company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.04. The medical device company earned $247.40 million during the quarter, compared to the consensus estimate of $255.70 million. NuVasive had a net margin of 6.36% and a return on equity of 13.65%. NuVasive's revenue was up 3.3% on a year-over-year basis. During the same period last year, the firm posted $0.40 EPS. View NuVasive's Earnings History.

When will NuVasive make its next earnings announcement?

NuVasive is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for NuVasive.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its FY17 earnings guidance on Tuesday, October, 24th. The company provided earnings per share (EPS) guidance of $1.91 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.99. The company issued revenue guidance of $1.030 billion, compared to the consensus revenue estimate of $1.09 billion.

Where is NuVasive's stock going? Where will NuVasive's stock price be in 2018?

15 analysts have issued 1 year target prices for NuVasive's shares. Their forecasts range from $60.00 to $90.00. On average, they anticipate NuVasive's share price to reach $71.64 in the next year. View Analyst Ratings for NuVasive.

What are Wall Street analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:

  • 1. Needham & Company LLC analysts commented, "We are upgrading NUVA to Buy from Underperform since: 1) we believe that consensus revenue and EPS estimates have declined to levels that are more realistic and likely conservative, 2) NUVA has done several acquisitions that probably aren’t fully factored into consensus revenue or EPS estimates (Vertera and SafePassage, which we estimate could add ~2% to NUVA’s 2018 revenue), 3) NUVA should see a significant benefit from tax reform (which we expect to increase its EPS by ~15% in 2018), and 4) we think NUVA shares are attractively valued considering the expected benefit from tax reform. We have raised our revenue and EPS estimates to reflect recent deals and tax reform." (1/4/2018)
  • 2. According to Zacks Investment Research, "NuVasive's recent quarterly performances were promising significantly driven by solid international growth. The last-reported third quarter marked the fourth consecutive one registering more than 20% growth in international business. However, overall sales in the quarter were impacted by procedural volume-related challenges in the United States and the adverse impact of hurricanes Harvey and Irma on NuVasive’s U.S. results and Maria on the international front. With chances of fourth-quarter revenues being affected by Maria in Puerto Rico and with the anticipated lower U.S. procedural volumes to continue, NuVasive is pressed to reduce its full-year guidance, which is disappointing. Also, the contraction in gross margin is a matter of concern. Overall, for the past six months, NuVasive has been trading below the broader industry." (12/19/2017)
  • 3. Canaccord Genuity analysts commented, "We note leading indicators of forward growth — new product flow (Less-ray, cervical iGA, Unite, pediatric deformity, expandable cages) and sales rep additions (+15 percent Y/Y in 2016) — should drive incremental growth opportunities entering the H2/16," the analyst said.On Track to Deliver Meaningful LeverageCanaccord Genuity believes the company is on track to deliver meaningful leverage over the next five years, although it expects M&A and continued investments to offset near-term improvements in operating margins."In sum, we continue to view the margin story positively but expect 2017 to be back-end loaded as NUVA realizes the benefits of sales force investments (building out peds team) and marketing efforts in Japan," the firm said.Guidance Reflects Changing SeasonalityThe firm noted that the company guided full-year revenues to $1.065 million, including a $10 million forex headwind, adjusted operating margins of 17.1 percent, up 100 basis points year-over-year, and earnings of $2 per share. However, the second quarter revenue guidance of $262 million was about $5 million below the consensus estimate, the firm added.According to the firm, this reflects the changing seasonality of the revenue cadence post the Ellipse Biotronic acquisitions. Concluding, the firm said, "We continue to believe that NuVasive is in prime share-taking position in the global spine market, driven by innovative new product flow, robust sales force additions, and broader tailwinds such as vendor consolidation."Furthermore, the margin expansion story remains intact and we see upside bias to estimates despite the second-half weighted guidance." (4/26/2017)
  • 4. UBS Group AG analysts commented, "The company's long-term operating margin goal of 25% was a key topic of discussion last week when we hosted NUVA for investor meetings. Management laid out a clear pathway to 25% operating margins (from 16.1% currently), which included: 1) 400 bps from in-source manufacturing; 2) 400 bps from asset efficiencies; 3) 400 bps from OUS scalability; and 4) 200 bps from sales force efficiencies, offset by 500 bps of R&D investment and pricing headwinds. We reiterate our Buy rating on NUVA and $82 price target and expect consistent execution and margin improvements to drive the stock higher." (3/20/2017)

Who are some of NuVasive's key competitors?

Who are NuVasive's key executives?

NuVasive's management team includes the folowing people:

  • Gregory T. Lucier, Chairman of the Board, Chief Executive Officer (Age 53)
  • Rajesh J. Asarpota, Chief Financial Officer, Executive Vice President (Age 50)
  • Joan B. Stafslien, Executive Vice President, General Counsel, Corporate Secretary (Age 52)
  • Carol A. Cox, Executive Vice President - External Affairs and Corporate Marketing (Age 52)
  • Peter Michael Leddy Ph.D., Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications (Age 53)
  • Matthew W. Link, Executive Vice President - Strategy, Technology and Corporate Development (Age 42)
  • Stephen Rozow, - Global Process Transformation (Age 48)
  • Vickie L. Capps, Independent Director (Age 55)
  • Peter C. Farrell Ph.D., Independent Director (Age 75)
  • Robert F. Friel, Independent Director (Age 61)

Who owns NuVasive stock?

NuVasive's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.55%), DnB Asset Management AS (0.32%), Profit Investment Management LLC (0.07%), Bank of Montreal Can (0.05%) and Fox Run Management L.L.C. (0.05%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.

Who bought NuVasive stock? Who is buying NuVasive stock?

NuVasive's stock was purchased by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Fox Run Management L.L.C., Bank of Montreal Can, Schwab Charles Investment Management Inc. and Profit Investment Management LLC. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.

How do I buy NuVasive stock?

Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuVasive's stock price today?

One share of NuVasive stock can currently be purchased for approximately $50.29.

How big of a company is NuVasive?

NuVasive has a market capitalization of $2.56 billion and generates $962.07 million in revenue each year. The medical device company earns $37.14 million in net income (profit) each year or $1.19 on an earnings per share basis. NuVasive employs 2,200 workers across the globe.

How can I contact NuVasive?

NuVasive's mailing address is 7475 Lusk Blvd, SAN DIEGO, CA 92121-5707, United States. The medical device company can be reached via phone at +1-858-9091800 or via email at [email protected]


MarketBeat Community Rating for NuVasive (NUVA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  540 (Vote Outperform)
Underperform Votes:  424 (Vote Underperform)
Total Votes:  964
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NuVasive (NASDAQ:NUVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.732.712.90
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $71.64$71.69$74.00$82.11
Price Target Upside: 37.80% upside21.18% upside36.58% upside1.99% upside

NuVasive (NASDAQ:NUVA) Consensus Price Target History

Price Target History for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ:NUVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018Wells Fargo & CoDowngradeOutperform -> Market Perform$65.00MediumView Rating Details
1/9/2018Piper Jaffray CompaniesReiterated RatingBuy$90.00HighView Rating Details
1/4/2018Needham & Company LLCUpgradeUnderperform -> Buy$71.00LowView Rating Details
12/14/2017BMO Capital MarketsReiterated RatingBuy$70.00MediumView Rating Details
12/13/2017BTIG ResearchSet Price TargetBuy$74.00LowView Rating Details
11/10/2017Royal Bank of CanadaLower Price TargetOutperform -> Outperform$75.00 -> $70.00N/AView Rating Details
10/25/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/AView Rating Details
10/25/2017Canaccord GenuityReiterated RatingBuy$75.00 -> $70.00N/AView Rating Details
10/19/2017BarclaysLower Price TargetOverweight$80.00 -> $65.00N/AView Rating Details
10/12/2017Robert W. BairdSet Price TargetHold$72.00 -> $60.00N/AView Rating Details
10/12/2017CowenSet Price TargetBuy$72.00N/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$74.00 -> $69.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$81.00 -> $70.00N/AView Rating Details
10/3/2017Jefferies GroupReiterated RatingBuy$79.00LowView Rating Details
9/21/2017GabelliReiterated RatingBuyLowView Rating Details
11/30/2016AegisInitiated CoverageBuy$72.00N/AView Rating Details
7/27/2016Brean CapitalBoost Price TargetBuy$60.00 -> $70.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

NuVasive (NASDAQ:NUVA) Earnings History and Estimates Chart

Earnings by Quarter for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ NUVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018$0.67N/AView Earnings Details
10/24/2017Q3 2017$0.48$0.52$255.70 million$247.40 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.44$0.46$261.95 million$260.60 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.37$0.38$250.52 million$249.86 millionViewN/AView Earnings Details
2/9/2017Q416$0.51$0.53$261.25 million$271.10 millionViewListenView Earnings Details
10/25/2016Q316$0.40$0.40$243.49 million$239.60 millionViewListenView Earnings Details
7/26/2016Q216$0.36$0.40$232.86 million$236.50 millionViewListenView Earnings Details
4/26/2016Q116$0.27$0.31$205.54 million$215.10 millionViewListenView Earnings Details
2/11/2016Q415$0.31$0.35$215.08 million$215.30 millionViewListenView Earnings Details
10/27/2015Q315$0.27$0.35$200.21 million$200.50 millionViewListenView Earnings Details
7/28/2015Q215$0.25$0.31$200.71 million$202.91 millionViewListenView Earnings Details
5/4/2015Q115$0.21$0.30$189.30 million$192.40 millionViewListenView Earnings Details
2/24/2015Q4$0.37$0.39$201.40 million$204.30 millionViewListenView Earnings Details
10/30/2014Q314$0.14$0.09$179.30 million$189.90 millionViewListenView Earnings Details
7/29/2014Q214$0.25$0.28$177.50 million$190.70 millionViewListenView Earnings Details
4/29/2014Q114$0.13$0.29$171.30 million$177.50 millionViewListenView Earnings Details
3/3/2014Q413$0.32$0.37$181.24 million$190.80 millionViewListenView Earnings Details
10/29/2013Q313$0.24$0.39$158.30 million$169.20 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.23$0.20$161.67 million$165.70 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.22$0.26$157.34 million$159.50 millionViewListenView Earnings Details
2/26/2013Q4 2012$0.21$0.34$156.35 million$165.80 millionViewListenView Earnings Details
10/24/2012$0.21$0.23ViewN/AView Earnings Details
7/25/2012$0.23$0.27ViewN/AView Earnings Details
4/30/2012$0.18$0.20ViewN/AView Earnings Details
2/22/2012$0.22$0.27ViewN/AView Earnings Details
10/27/2011$0.24$0.26ViewN/AView Earnings Details
7/25/2011$0.28$0.30ViewN/AView Earnings Details
5/5/2011$0.19$0.24ViewN/AView Earnings Details
2/23/2011$0.42$0.46ViewN/AView Earnings Details
10/28/2010Q3 2010$0.26$0.29ViewN/AView Earnings Details
7/27/2010Q2 2010$0.18$0.24ViewN/AView Earnings Details
4/20/2010Q1 2010$0.07$0.09ViewN/AView Earnings Details
2/25/2010Q4 2009$0.11$0.11ViewN/AView Earnings Details
10/20/2009Q3 2009$0.05$0.15ViewN/AView Earnings Details
7/23/2009Q2 2009($0.02)$0.07ViewN/AView Earnings Details
4/22/2009Q1 2009($0.20)($0.02)ViewN/AView Earnings Details
2/25/2009Q4 2008$0.12$0.16ViewN/AView Earnings Details
10/22/2008Q3 2008$0.01$0.04ViewN/AView Earnings Details
7/24/2008Q2 2008($0.03)($0.01)ViewN/AView Earnings Details
4/22/2008Q1 2008($0.10)($0.10)ViewN/AView Earnings Details
2/19/2008Q4 2007($0.04)($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

NuVasive (NASDAQ:NUVA) Earnings Estimates

2018 EPS Consensus Estimate: $2.26
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.41$0.51$0.45
Q2 20183$0.55$0.59$0.57
Q3 20183$0.57$0.58$0.58
Q4 20183$0.63$0.71$0.66
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for NuVasive (NASDAQ:NUVA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

NuVasive (NASDAQ NUVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for NuVasive (NASDAQ:NUVA)
Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ NUVA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/29/2017Gregory T LucierCEOBuy2,000$61.52$123,040.00View SEC Filing  
8/18/2017Lesley H. HoweDirectorSell3,970$64.64$256,620.80View SEC Filing  
8/17/2017Gregory T LucierCEOBuy5,000$66.22$331,100.00View SEC Filing  
8/1/2017Peter Michael LeddyEVPBuy7,850$63.88$501,458.00View SEC Filing  
3/8/2017Jason HannonInsiderSell24,840$74.22$1,843,624.80View SEC Filing  
2/14/2017Lesley H. HoweDirectorSell6,049$73.26$443,149.74View SEC Filing  
12/12/2016Matthew LinkInsiderSell10,303$67.99$700,500.97View SEC Filing  
11/4/2016Michael D OhalleranDirectorBuy4,200$58.26$244,692.00View SEC Filing  
11/2/2016Patrick MilesDirectorBuy16,967$58.97$1,000,543.99View SEC Filing  
11/1/2016Patrick MilesDirectorBuy16,667$59.00$983,353.00View SEC Filing  
10/31/2016Joan StafslienEVPBuy5,000$59.68$298,400.00View SEC Filing  
10/31/2016Michael D OhalleranDirectorBuy4,205$59.47$250,071.35View SEC Filing  
8/23/2016Jason HannonEVPSell2,625$64.80$170,100.00View SEC Filing  
8/2/2016Jason HannonEVPSell11,184$62.70$701,236.80View SEC Filing  
8/2/2016Lesley H. HoweDirectorSell3,602$62.44$224,908.88View SEC Filing  
7/20/2016Jason HannonEVPSell2,920$62.80$183,376.00View SEC Filing  
6/16/2016Jason HannonEVPSell14,534$57.57$836,722.3837,616View SEC Filing  
1/6/2016Patrick MilesCOOSell10,723$54.03$579,363.6931,646View SEC Filing  
12/16/2015Patrick MilesCOOSell9,127$52.56$479,715.1231,646View SEC Filing  
12/7/2015Quentin S BlackfordCFOSell15,000$51.10$766,500.002,599View SEC Filing  
12/3/2015Patrick MilesCOOSell5,873$52.51$308,391.2340,773View SEC Filing  
11/2/2015Patrick MilesCOOSell15,000$48.12$721,800.0032,627View SEC Filing  
10/5/2015Matthew LinkinsiderSell1,714$50.72$86,934.0853,089View SEC Filing  
10/3/2015Quentin S BlackfordCFOSell5,000$36.30$181,500.00View SEC Filing  
10/1/2015Patrick MilesCOOSell15,000$48.10$721,500.0047,627View SEC Filing  
9/8/2015Russell PowersEVPSell5,806$51.64$299,821.8462,024View SEC Filing  
9/2/2015Jason HannonEVPSell11,962$52.02$622,263.2418,565View SEC Filing  
9/1/2015Patrick MilesCOOSell15,000$52.03$780,450.0062,627View SEC Filing  
8/31/2015Patrick MilesCOOSell15,000$53.34$800,100.0062,627View SEC Filing  
7/20/2015Jason HannonEVPSell15,000$49.60$744,000.00View SEC Filing  
6/15/2015Gregory T LucierCEOBuy4,491$49.49$222,259.59View SEC Filing  
6/12/2015Gregory T LucierCEOBuy8,000$50.10$400,800.00View SEC Filing  
6/10/2015Gregory T LucierCEOBuy10,000$49.10$491,000.00View SEC Filing  
6/8/2015Gregory T LucierCEOBuy10,000$49.26$492,600.00View SEC Filing  
6/4/2015Gregory T LucierCEOBuy10,000$49.71$497,100.00View SEC Filing  
6/2/2015Gregory T LucierCEOBuy8,000$49.96$399,680.00View SEC Filing  
6/2/2015Patrick MilesCOOSell4,194$49.47$207,477.18View SEC Filing  
5/29/2015Jack R BlairDirectorSell3,703$50.16$185,742.48View SEC Filing  
5/28/2015Gregory T LucierCEOBuy34,000$49.25$1,674,500.00View SEC Filing  
5/28/2015Russell PowersEVPSell8,042$49.00$394,058.00View SEC Filing  
5/19/2015Patrick MilesCOOSell15,000$47.52$712,800.00View SEC Filing  
5/1/2015Russell PowersEVPSell11,881$45.21$537,140.01View SEC Filing  
4/24/2015Russell PowersEVPSell3,888$44.07$171,344.16View SEC Filing  
3/13/2015Patrick MilesCOOSell7,920$45.52$360,518.40View SEC Filing  
3/9/2015Alexis V LukianovCEOSell5,313$44.82$238,128.66View SEC Filing  
3/3/2015Matthew LinkInsiderSell7,500$44.46$333,450.00View SEC Filing  
3/2/2015Jason HannonEVPSell5,085$45.06$229,130.10View SEC Filing  
2/9/2015Alexis V LukianovCEOSell5,454$46.10$251,429.40View SEC Filing  
2/5/2015Matthew LinkInsiderSell4,078$45.77$186,650.06View SEC Filing  
2/3/2015Patrick MilesCOOSell15,000$45.53$682,950.00View SEC Filing  
1/28/2015Keith ValentineCOOSell6,970$46.96$327,311.20View SEC Filing  
1/12/2015Alexis V LukianovCEOSell7,452$49.69$370,289.88View SEC Filing  
1/5/2015Jason HannonEVPSell12,117$46.82$567,317.94View SEC Filing  
1/5/2015Patrick MilesInsiderSell15,000$46.61$699,150.00View SEC Filing  
12/30/2014Jason HannonEVPSell15,000$47.63$714,450.00View SEC Filing  
12/29/2014Jason HannonEVPSell3,146$47.57$149,655.22View SEC Filing  
12/24/2014Patrick MilesInsiderSell15,000$47.52$712,800.00View SEC Filing  
12/19/2014Keith ValentineCOOSell5,893$47.78$281,567.54View SEC Filing  
12/1/2014Keith ValentineCOOSell2,500$43.66$109,150.00View SEC Filing  
11/19/2014Keith ValentineCOOSell5,582$43.32$241,812.24View SEC Filing  
11/19/2014Quentin S BlackfordCFOSell7,698$43.41$334,170.18View SEC Filing  
11/7/2014Alexis V LukianovCEOSell25,000$41.40$1,035,000.00View SEC Filing  
11/3/2014Keith ValentineCOOSell2,500$40.61$101,525.00View SEC Filing  
10/2/2014Keith ValentineCOOSell2,500$35.00$87,500.00View SEC Filing  
9/2/2014Keith ValentineCOOSell2,500$35.14$87,850.00View SEC Filing  
8/1/2014Keith ValentineCOOSell2,500$37.11$92,775.00View SEC Filing  
8/1/2014Michael LambertCFOSell4,010$37.11$148,811.10View SEC Filing  
7/30/2014Jason HannonEVPSell5,000$39.00$195,000.00View SEC Filing  
7/10/2014Russell PowersEVPSell3,200$33.43$106,976.00View SEC Filing  
7/1/2014Keith ValentineCOOSell2,500$35.65$89,125.00View SEC Filing  
7/1/2014Michael LambertCFOSell23,225$35.48$824,023.00View SEC Filing  
6/20/2014Keith ValentineCOOSell5,000$35.00$175,000.00View SEC Filing  
6/20/2014Russell PowersEVPSell9,526$35.00$333,410.00View SEC Filing  
5/5/2014Robert HuntDirectorSell20,000$34.25$685,000.0034,500View SEC Filing  
5/2/2014Michael LambertCFOSell13,096$33.07$433,084.7251,695View SEC Filing  
4/1/2014Keith ValentineCOOSell2,500$38.41$96,025.0088,985View SEC Filing  
3/11/2014Peter FarrellDirectorSell48,000$36.88$1,770,240.006,794View SEC Filing  
1/21/2014Jason HannonEVPSell10,095$36.60$369,477.008,899View SEC Filing  
1/16/2014Keith ValentineCOOSell20,000$37.96$759,200.0044,226View SEC Filing  
1/7/2014Alexis LukianovCEOSell34,217$34.29$1,173,300.9355,740View SEC Filing  
1/7/2014Craig HunsakerSVPSell4,980$35.00$174,300.0021,142View SEC Filing  
12/30/2013Craig HunsakerSVPSell4,275$32.10$137,227.5024,980View SEC Filing  
12/23/2013Michael LambertCFOSell17,091$32.49$555,286.5913,096View SEC Filing  
11/7/2013Alexis LukianovCEOSell5,000$31.45$157,250.0072,827View SEC Filing  
10/30/2013Jason HannonEVPSell2,334$28.90$67,452.60View SEC Filing  
10/30/2013Patrick MilesInsiderSell21,223$31.10$660,035.30View SEC Filing  
10/28/2013Patrick MilesInsiderSell7,331$25.72$188,553.32View SEC Filing  
10/21/2013Russell PowersVPSell12,500$25.39$317,375.00View SEC Filing  
10/11/2013Jason HannonEVPSell1,000$26.00$26,000.0019,991View SEC Filing  
10/7/2013Jason HannonEVPSell8,705$23.99$208,832.9519,991View SEC Filing  
10/7/2013Michael LambertCFOSell15,442$24.04$371,225.6830,187View SEC Filing  
8/6/2013Richard Treharne IIIDirectorBuy2,000$23.26$46,520.00View SEC Filing  
7/12/2013Craig E HunsakerSVPSell2,000$27.00$54,000.00View SEC Filing  
7/8/2013Alexis V LukianovCEOSell5,000$25.74$128,700.00View SEC Filing  
7/1/2013Keith ValentineCOOSell1,698$25.00$42,450.00View SEC Filing  
5/13/2013Alexis V LukianovCEOSell7,500$22.71$170,325.00View SEC Filing  
5/8/2013Peter Michael LeddyDirectorBuy2,400$22.24$53,376.00View SEC Filing  
5/7/2013Alexis V LukianovCEOSell12,500$22.11$276,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NuVasive (NASDAQ NUVA) News Headlines

Source:
DateHeadline
Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Accuray, K2M Group, NuVasive, and NovoCureQuotidian Technical Highlights on Selected Medical Equipment Stocks -- Accuray, K2M Group, NuVasive, and NovoCure
www.bizjournals.com - January 18 at 11:16 AM
Nuvasive Enters Oversold Territory (NUVA)Nuvasive Enters Oversold Territory (NUVA)
www.nasdaq.com - January 17 at 4:38 PM
NuVasive (NUVA) Rating Lowered to Strong Sell at BidaskClubNuVasive (NUVA) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - January 14 at 10:30 PM
Global Spine Market 2017-2021 with Focus on Spinal Fusion: Industry Analysis & Outlook - Rising Cases of Spinal Cord Injury Driving the Market - Research and MarketsGlobal Spine Market 2017-2021 with Focus on Spinal Fusion: Industry Analysis & Outlook - Rising Cases of Spinal Cord Injury Driving the Market - Research and Markets
www.businesswire.com - January 10 at 4:36 PM
Intraoperative Neuromonitoring Market - Global Opportunity Analysis and Industry Forecast, 2014-2022Intraoperative Neuromonitoring Market - Global Opportunity Analysis and Industry Forecast, 2014-2022
www.prnewswire.com - January 10 at 4:36 PM
NuVasive Q4 Preliminary Results Fail to Cheer InvestorsNuVasive Q4 Preliminary Results Fail to Cheer Investors
finance.yahoo.com - January 10 at 10:24 AM
NuVasive (NUVA) Rating Reiterated by Piper Jaffray CompaniesNuVasive (NUVA) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - January 9 at 1:38 PM
Celgene, Dave& Busters slide while Kohls and Crocs riseCelgene, Dave& Buster's slide while Kohl's and Crocs rise
www.latimes.com - January 9 at 10:13 AM
NuVasive, Inc. (NUVA) Given Average Recommendation of "Buy" by BrokeragesNuVasive, Inc. (NUVA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 8 at 10:02 PM
Here's What Pressured NuVasive, Inc. Stock TodayHere's What Pressured NuVasive, Inc. Stock Today
finance.yahoo.com - January 8 at 4:42 PM
Heres What Pressured NuVasive, Inc. Stock TodayHere's What Pressured NuVasive, Inc. Stock Today
www.fool.com - January 8 at 2:37 PM
NuVasive Sees FY17 Revenue In Line With Prior Guidance - Quick FactsNuVasive Sees FY17 Revenue In Line With Prior Guidance - Quick Facts
www.nasdaq.com - January 8 at 10:30 AM
NuVasive Announces Preliminary Unaudited Full Year 2017 Revenue Results And Preliminary 2018 OutlookNuVasive Announces Preliminary Unaudited Full Year 2017 Revenue Results And Preliminary 2018 Outlook
finance.yahoo.com - January 8 at 10:30 AM
Integra Lifesciences (IART) versus NuVasive (NUVA) Critical ContrastIntegra Lifesciences (IART) versus NuVasive (NUVA) Critical Contrast
www.americanbankingnews.com - January 6 at 11:36 PM
Stocks To Watch: CES Headlines Blockbuster Conference SlateStocks To Watch: CES Headlines Blockbuster Conference Slate
www.nasdaq.com - January 6 at 10:16 AM
NuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $272.74 MillionNuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $272.74 Million
www.americanbankingnews.com - January 6 at 6:32 AM
NuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF Procedures - PR Newswire (press release)NuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF Procedures - PR Newswire (press release)
www.prnewswire.com - January 4 at 4:37 PM
NuVasive To Present At The 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)NuVasive To Present At The 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - January 4 at 4:37 PM
Medtech Player Bounds On Upgrade Amid Tax Reform, AcquisitionsMedtech Player Bounds On Upgrade Amid Tax Reform, Acquisitions
finance.yahoo.com - January 4 at 4:37 PM
NuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF ProceduresNuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF Procedures
finance.yahoo.com - January 4 at 10:14 AM
$0.56 Earnings Per Share Expected for NuVasive, Inc. (NUVA) This Quarter$0.56 Earnings Per Share Expected for NuVasive, Inc. (NUVA) This Quarter
www.americanbankingnews.com - January 4 at 5:10 AM
NuVasive To Present At The 36th Annual J.P. Morgan Healthcare ConferenceNuVasive To Present At The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 4:40 PM
BidaskClub Downgrades NuVasive (NUVA) to SellBidaskClub Downgrades NuVasive (NUVA) to Sell
www.americanbankingnews.com - December 28 at 3:26 PM
ETFs with exposure to NuVasive, Inc. : December 28, 2017ETFs with exposure to NuVasive, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 12:53 PM
Comparing NuVasive (NUVA) and Sientra (SIEN)Comparing NuVasive (NUVA) and Sientra (SIEN)
www.americanbankingnews.com - December 24 at 3:30 PM
NuVasive Comments On Expected Impact Of US Tax Reform - PR Newswire (press release)NuVasive Comments On Expected Impact Of US Tax Reform - PR Newswire (press release)
www.prnewswire.com - December 23 at 12:33 AM
BRIEF-NuVasive Comments On Expected Impact Of U.S. Tax ReformBRIEF-NuVasive Comments On Expected Impact Of U.S. Tax Reform
www.reuters.com - December 21 at 10:18 AM
NuVasive Comments On Expected Impact Of U.S. Tax ReformNuVasive Comments On Expected Impact Of U.S. Tax Reform
finance.yahoo.com - December 21 at 10:18 AM
Medical device maker says savings from new tax law to fuel innovation and growthMedical device maker says savings from new tax law to fuel innovation and growth
finance.yahoo.com - December 21 at 10:18 AM
NuVasive (NUVA) Global Prospects Solid, Pricing Woes RemainNuVasive (NUVA) Global Prospects Solid, Pricing Woes Remain
finance.yahoo.com - December 20 at 10:23 AM
Zacks: Analysts Anticipate NuVasive, Inc. (NUVA) Will Announce Quarterly Sales of $272.74 MillionZacks: Analysts Anticipate NuVasive, Inc. (NUVA) Will Announce Quarterly Sales of $272.74 Million
www.americanbankingnews.com - December 20 at 6:08 AM
NuVasive (NUVA) Lifted to "Hold" at Zacks Investment ResearchNuVasive (NUVA) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - December 19 at 3:20 PM
Stock Review for Medical Equipments Investors -- Align Technology, K2M Group, NuVasive, and Nxstage Medical - PR Newswire (press release)Stock Review for Medical Equipment's Investors -- Align Technology, K2M Group, NuVasive, and Nxstage Medical - PR Newswire (press release)
www.prnewswire.com - December 18 at 10:43 AM
NuVasive (NUVA) Stock Rating Reaffirmed by BMO Capital MarketsNuVasive (NUVA) Stock Rating Reaffirmed by BMO Capital Markets
www.americanbankingnews.com - December 16 at 6:24 PM
NuVasive (NUVA) to Acquire SafePassage, Strengthens IONM - NasdaqNuVasive (NUVA) to Acquire SafePassage, Strengthens IONM - Nasdaq
www.nasdaq.com - December 16 at 4:32 PM
NuVasive Appoints Experienced Spine Executive Michael Piccirillo To Lead New Global Surgeon Education Platform - PR Newswire (press release)NuVasive Appoints Experienced Spine Executive Michael Piccirillo To Lead New Global Surgeon Education Platform - PR Newswire (press release)
www.prnewswire.com - December 16 at 4:32 PM
NuVasive (NUVA) Upgraded to Hold at BidaskClubNuVasive (NUVA) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - December 16 at 12:44 PM
NuVasive, Inc. (NUVA) Receives Consensus Rating of "Buy" from AnalystsNuVasive, Inc. (NUVA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 14 at 9:28 PM
NuVasive Appoints Experienced Spine Executive Michael Piccirillo To Lead New Global Surgeon Education PlatformNuVasive Appoints Experienced Spine Executive Michael Piccirillo To Lead New Global Surgeon Education Platform
finance.yahoo.com - December 14 at 5:06 PM
NuVasive (NUVA) to Acquire SafePassage, Strengthens IONMNuVasive (NUVA) to Acquire SafePassage, Strengthens IONM
finance.yahoo.com - December 14 at 10:28 AM
BTIG Research Analysts Give NuVasive (NUVA) a $74.00 Price TargetBTIG Research Analysts Give NuVasive (NUVA) a $74.00 Price Target
www.americanbankingnews.com - December 13 at 3:34 PM
NuVasive (NUVA) Enters Agreement to Acquire SafePassageNuVasive (NUVA) Enters Agreement to Acquire SafePassage
www.streetinsider.com - December 13 at 10:41 AM
NuVasive To Buy IONM Services Provider SafePassage; Terms Not DisclosedNuVasive To Buy IONM Services Provider SafePassage; Terms Not Disclosed
www.nasdaq.com - December 13 at 10:41 AM
BRIEF-Nuvasive To Acquire SafepassageBRIEF-Nuvasive To Acquire Safepassage
www.reuters.com - December 12 at 4:54 PM
NuVasive To Acquire SafePassageNuVasive To Acquire SafePassage
www.prnewswire.com - December 12 at 4:30 PM
Vascular Dynamics, Inc.: Vascular Dynamics Appoints Ed Roschak CEOVascular Dynamics, Inc.: Vascular Dynamics Appoints Ed Roschak CEO
www.finanznachrichten.de - December 4 at 10:19 AM
Financial Comparison: West Pharmaceutical Services (WST) vs. NuVasive (NUVA)Financial Comparison: West Pharmaceutical Services (WST) vs. NuVasive (NUVA)
www.americanbankingnews.com - November 24 at 5:18 AM
Spinal Implants Market in Europe to Cross US$ 4 Billion By 2024Spinal Implants Market in Europe to Cross US$ 4 Billion By 2024
www.marketwatch.com - November 23 at 7:01 AM
NuVasive, Inc. (NUVA) Receives Consensus Recommendation of "Buy" from BrokeragesNuVasive, Inc. (NUVA) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 19 at 5:32 PM
NuVasive To Participate In The 29th Annual Piper Jaffray Healthcare Conference - PR Newswire (press release)NuVasive To Participate In The 29th Annual Piper Jaffray Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - November 18 at 9:04 AM

SEC Filings

NuVasive (NASDAQ:NUVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NuVasive (NASDAQ:NUVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NuVasive (NASDAQ NUVA) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.